Literature DB >> 9549052

Decreased insulin content and secretion in RIN 1046-38 cells overexpressing alpha 2-adrenergic receptors.

M S Rodriguez-Pena1, R Collins, C Woodard, A M Spiegel.   

Abstract

Several Gi-protein-coupled receptors normally expressed in islet beta-cells inhibit insulin secretion on binding of their respective agonists. To study the effect of supraphysiologic expression of such a receptor in insulin-secreting beta-cells, we stably transfected cDNA encoding the mouse alpha 2a-adrenergic receptor into RIN 1046-38 cells. Four different cell lines were selected, each overexpressing the alpha 2a-adrenergic receptor to varying degrees. Cell lines showing the highest level of receptor expression showed significantly reduced insulin content, and reduced basal and stimulated insulin secretion. Pertussis toxin (PTX) treatment of cells was able to reverse partially the reduced insulin secretory response. Our results suggest that overexpression of a Gi-protein-coupled receptor in beta-cells causes tonic inhibition of both insulin synthesis and secretion. Abnormalities in expression or function of such receptors could be a contributory factor in the impaired insulin secretion present in type II diabetes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9549052     DOI: 10.1007/BF02778148

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  20 in total

1.  G-proteins and hormonal inhibition of insulin secretion from HIT-T15 cells and isolated rat islets.

Authors:  E R Seaquist; A R Neal; K D Shoger; T F Walseth; R P Robertson
Journal:  Diabetes       Date:  1992-11       Impact factor: 9.461

Review 2.  Mutations in G proteins and G protein-coupled receptors in endocrine disease.

Authors:  A M Spiegel
Journal:  J Clin Endocrinol Metab       Date:  1996-07       Impact factor: 5.958

3.  Transcribing diabetes.

Authors:  J A Todd
Journal:  Nature       Date:  1996-12-05       Impact factor: 49.962

Review 4.  Mechanisms of inhibition of insulin release.

Authors:  G W Sharp
Journal:  Am J Physiol       Date:  1996-12

5.  Somatostatin and epinephrine decrease insulin messenger ribonucleic acid in HIT cells through a pertussis toxin-sensitive mechanism.

Authors:  H J Zhang; J B Redmon; J M Andresen; R P Robertson
Journal:  Endocrinology       Date:  1991-11       Impact factor: 4.736

Review 6.  Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins.

Authors:  R J Lefkowitz; S Cotecchia; P Samama; T Costa
Journal:  Trends Pharmacol Sci       Date:  1993-08       Impact factor: 14.819

7.  Modulation of glucose-induced insulin secretion from a rat clonal beta-cell line.

Authors:  S A Clark; B L Burnham; W L Chick
Journal:  Endocrinology       Date:  1990-12       Impact factor: 4.736

8.  Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor.

Authors:  C A Milano; L F Allen; H A Rockman; P C Dolber; T R McMinn; K R Chien; T D Johnson; R A Bond; R J Lefkowitz
Journal:  Science       Date:  1994-04-22       Impact factor: 47.728

9.  Noradrenaline induces supersensitivity of adenylyl cyclase in NG108-15 and HT29-18 cells but not in the beta-cell RINm5F.

Authors:  A M McDermott; G W Sharp
Journal:  Cell Signal       Date:  1995-03       Impact factor: 4.315

10.  Pharmacological characterization of alpha-2 adrenergic receptor subtype involved in the release of insulin from isolated rat pancreatic islets.

Authors:  R Niddam; I Angel; S Bidet; S Z Langer
Journal:  J Pharmacol Exp Ther       Date:  1990-09       Impact factor: 4.030

View more
  2 in total

Review 1.  Evolving insights regarding mechanisms for the inhibition of insulin release by norepinephrine and heterotrimeric G proteins.

Authors:  Susanne G Straub; Geoffrey W G Sharp
Journal:  Am J Physiol Cell Physiol       Date:  2012-04-04       Impact factor: 4.249

Review 2.  Potential Therapeutic Targeting Neurotransmitter Receptors in Diabetes.

Authors:  Xiaohui Pan; Shibing Tao; Nanwei Tong
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-20       Impact factor: 6.055

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.